A critical appraisal of structure-based drug design

IDrugs

Volumn 9, Issue 2, 2006, Pages 114-118

  Tintelnot Blomley, Marina ^a   Lewis, Richard A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Crystallography; Drug design; High throughput screening; Protein flexibility; Protein ligand interaction

Indexed keywords

ALISKIREN; ESTER DERIVATIVE; HUMAN SERUM ALBUMIN; IMATINIB; NEW DRUG; PHOSPHODIESTERASE IV INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ANALYTICAL EQUIPMENT; ARTICLE; CLINICAL TRIAL; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG RESISTANCE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; PROCESS OPTIMIZATION; PROTEIN STRUCTURE; SIDE EFFECT; X RAY CRYSTALLOGRAPHY;

COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 32544452857     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Bergner A, Günther J: Structural aspects of binding site similarity: A 3D upgrade for chemogenomics. In: Chemogenomics in Drug Discovery: A Medicinal Chemistry Perspective. Kubinyi H, Müller G (Eds), Wiley-VCH Verlag, Weinheim, Germany (2004):97-135.
2. Congreve M, Murray CW, Blundell TL: Structural biology and drug discovery. Drug Discov Today (2005) 10(13):895-907.
3. Williams SP, Kuyper LF, Pearce KH: Recent applications of protein crystallography and structure-guided drug design. Curr Opin Chem Biol (2005) 9(4):371-380.
4. Hartshorn MJ, Murray CW, Cleasby A, Frederickson M, Tickle IJ, Jhoti H: Fragment-based lead discovery using X-ray crystallography. J Med Chem (2005) 48(2):403-413.
5. Teague SJ: Implications of protein flexibility in drug discovery. Nature Rev Drug Discov (2003) 2(7):527-541.
6. Schmitt S, Kuhn D, Kiebe G: A new method to detect related function among proteins independent of sequence and fold homology. J Mol Biol (2002) 323(2):387-406.
7. King NM, Prabu-Jeyabalan M, Nalivaika EA, Schiffer CA: Combating susceptibility to drug resistance: Lessons from HIV-1 protease. Chem Biol (2004) 11(10)1333-1338.
8. Lipinski CA: Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods (2000) 44(1):235-249.
9. Congreve M, Carr R, Murray C, Jhoti H: A 'Rule of Threat' for fragment-based lead discovery? Drug Discov Today (2005) 8(19):876-877.
10. Abad-Zapatero C, Metz JT: Ligand efficiency indices as guideposts for drug discovery. Drug Discov Today (2005) 10(7):464-469.